2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Btk

Btk

Bruton tyrosine kinase

Btk

Related Products

PDF 1.37 MB

Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.

Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-162081
    BTK-IN-32
    		Inhibitor
    BTK-IN-32 (compound C2) is a potent inhibitor of BTK. BTK-IN-32 activates full-length BTK and smaller multidomain BTK fragments instead of the isolated kinase domain.
    BTK-IN-32
  • HY-173126
    BTK ligand-14
    		Inhibitor
    BTK ligand-14 is a PROTAC target protein ligand that targets BTK and can be used for the synthesis of FDU73 (HY-173125).
    BTK ligand-14
  • HY-143730
    BTK inhibitor 20
    		Inhibitor
    BTK inhibitor 20 is a potent BTK inhibitor with an IC50 of 8 nM.
    BTK inhibitor 20
  • HY-147754
    JAK3/BTK-IN-6
    		Inhibitor
    JAK3/BTK-IN-6 (compound 14h) is a potent BTK and JAK3 dual inhibitor, with IC50 values of 0.6 and 0.4 nM, respectively. JAK3/BTK-IN-6 shows good metabolic stability in human liver microsome. JAK3/BTK-IN-6 can be used for hematological and immune diseases research.
    JAK3/BTK-IN-6
  • HY-153705
    BTK-IN-25
    		Inhibitor
    BTK-IN-25 (compound 71) is a potent inhibitor of BTK, and inhibits BTK(C481S) with an IC50 value of 0.77 nM. BTK-IN-25 inhibits BTK in DOHH2 cells with an IC50 value of 1 nM.
    BTK-IN-25
  • HY-143719
    JAK3/BTK-IN-4
    		Inhibitor
    JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)
    JAK3/BTK-IN-4
  • HY-147582
    BTK-IN-12
    		Inhibitor
    BTK-IN-12 is a potent BTK inhibitor with IC50s of 1.2 nM and 0.8 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022037649A1; compound 8).
    BTK-IN-12
  • HY-163827
    ABBV-992
    		Inhibitor
    ABBV-992 is a potent and selective BTK inhibitor. ABBV-992 can be used for the research of cancer.
    ABBV-992
  • HY-168427
    Avitinib maleate dihydrate
    		Inhibitor
    Avitinib (Abivertinib) maleate dihydrate is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC50 values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib maleate dihydrate is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib maleate dihydrate shows anticancer effects.
    Avitinib maleate dihydrate
  • HY-143901
    EGFR-IN-40
    		Inhibitor
    EGFR-IN-40 (compound 3z) is a potent BTK, EGFR, and ITK inhibitor with IC50 values of 1.2 nM, 5.3 nM, and 46.1 nM, respectively.
    EGFR-IN-40
  • HY-179948
    BTK-IN-45
    		Inhibitor
    BTK-IN-45 (Compound 6b) is a potent, reversible, and selective BTK inhibitor with an IC50 of 1.14 μM. BTK-IN-45 also exhibits modest inhibition for LCK. BTK-IN-45 can be used in the research of cancers, including leukemia.
    BTK-IN-45
  • HY-W062695
    (R)-Acalabrutinib
    		Inhibitor
    (R)-Acalabrutinib ((R)-ACP-196) is the enantiomer of Acalabrutinib (HY-17600). (R)-Acalabrutinib is an inhibitor for Bruton’s tyrosine kinase (BTK).
    (R)-Acalabrutinib
  • HY-110113
    CTA056
    		Inhibitor
    CTA056 is an ITK (IL-2-inducible T-cell kinase) inhibitor with an IC50 of 0.1 μM. CTA056 selectively targets malignant T cells and modulates oncomirs. CTA056 induces apoptosis and is a potential therapeutic agent for the research of T-cell leukemia and lymphoma.
    CTA056
  • HY-159589
    BTK-IN-37
    		Inhibitor
    BTK-IN-37 (compound 8d) is a BTK inhibitor that can induce apoptosis in cancer cells. BTK-IN-37 targets BTK with Ki and IC50 of 5.07 nM and 3.6 nM, respectively. BTK-IN-37 can also selectively induce enrichment of genes involved in necroptosis and pyroptosis.
    BTK-IN-37
  • HY-152212
    BTK-IN-19
    		Inhibitor
    BTK-IN-19 (Compound 51) is a reversible BTK inhibitor with an IC50 of <0.001 μM.
    BTK-IN-19
  • HY-151211
    BTK-IN-16
    		Inhibitor 98.93%
    BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with IC50s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia.
    BTK-IN-16
  • HY-153536
    PROTAC BTK Degrader-3
    		Inhibitor
    PROTAC BTK Degrader-3 is a potent BTK degrader with a DC50 value of 10.9 nM of BTK degradation in Mino cells. PROTAC BTK Degrader-3 has the potential for B-cell malignancies, including chronic lymphoid malignancies research.
    PROTAC BTK Degrader-3
  • HY-141689
    BTK-IN-3
    		Inhibitor
    BTK-IN-3 (example 1) is an inhibitor of BTK. BTK-IN-3 can used to study cancer.
    BTK-IN-3
  • HY-124605
    IQS-019
    		Inhibitor
    IQS-019 is a B cell receptor (BCR) kinase inhibitor. IQS-019 can inhibit the de-phosphorylation of constitutive and IgM-activated Syk, Lyn, and Btk. IQS-019 can inhibit cell proliferation, migration and induce apoptosis. IQS-019 exhibits antitumor activity and can be used for the research of cancer, such as B cell lymphoma.
    IQS-019
  • HY-143716
    JAK3/BTK-IN-1
    		Inhibitor
    JAK3/BTK-IN-1 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002).
    JAK3/BTK-IN-1
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity